Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Non-Current Deffered Revenue (2016 - 2018)

Historic Non-Current Deffered Revenue for Cardiff Oncology (CRDF) over the last 3 years, with Q4 2018 value amounting to $1.1 million.

  • Cardiff Oncology's Non-Current Deffered Revenue fell 785.74% to $1.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $1.1 million, marking a year-over-year decrease of 785.74%. This contributed to the annual value of $1.1 million for FY2018, which is 785.74% down from last year.
  • According to the latest figures from Q4 2018, Cardiff Oncology's Non-Current Deffered Revenue is $1.1 million, which was down 785.74% from $1.2 million recorded in Q3 2018.
  • Over the past 5 years, Cardiff Oncology's Non-Current Deffered Revenue peaked at $1.4 million during Q3 2016, and registered a low of $1.0 million during Q2 2018.
  • In the last 3 years, Cardiff Oncology's Non-Current Deffered Revenue had a median value of $1.2 million in 2017 and averaged $1.2 million.
  • In the last 5 years, Cardiff Oncology's Non-Current Deffered Revenue plummeted by 2029.12% in 2017 and then skyrocketed by 440.41% in 2018.
  • Quarter analysis of 3 years shows Cardiff Oncology's Non-Current Deffered Revenue stood at $1.4 million in 2016, then decreased by 13.83% to $1.2 million in 2017, then decreased by 7.86% to $1.1 million in 2018.
  • Its last three reported values are $1.1 million in Q4 2018, $1.2 million for Q3 2018, and $1.0 million during Q2 2018.